Merck progresses toward completion of Sigma-Aldrich acquisition
Closing of transaction expected within next two months
Sigma-Aldrich shareholders approved the merger with Merck. Merck has also completed its capital markets activities to finance the transaction with the placement of a € 2.1 billion bond.
The planned acquisition of Sigma-Aldrich for approximately US$ 17 billion (€ 13.1 billion), which was announced in September 2014, is a key element of Merck’s “Fit for 2018” transformation and growth program. Establishing one of the leading players in the $ 130 billion global life science industry, the transaction presents an opportunity for both companies and their customers. Once the transaction has been completed, Merck will be able to serve life science customers around the world with a highly attractive set of established brands and an efficient supply chain that can support the delivery of more than 300,000 products.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.